V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 2.36 USD -1.26% Market Closed
Market Cap: 68.1m USD

Wall Street
Price Targets

VTGN Price Targets Summary
VistaGen Therapeutics Inc

Wall Street analysts forecast VTGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VTGN is 13.26 USD with a low forecast of 12.12 USD and a high forecast of 15.75 USD.

Lowest
Price Target
12.12 USD
414% Upside
Average
Price Target
13.26 USD
462% Upside
Highest
Price Target
15.75 USD
567% Upside
VistaGen Therapeutics Inc Competitors:
Price Targets
PRQR
ProQR Therapeutics NV
404% Upside
4587
PeptiDream Inc
106% Upside
2487
Cutia Therapeutics
11% Downside
086890
Isu Abxis Co Ltd
90% Upside
BBIO
BridgeBio Pharma Inc
58% Upside
2171
CARsgen Therapeutics Holdings Ltd
53% Downside
002675
Yantai Dongcheng Biochemicals Co Ltd
2% Upside
SRZN
Surrozen Inc
319% Upside

Revenue
Forecast

Revenue Estimate
VistaGen Therapeutics Inc

The compound annual growth rate of VistaGen Therapeutics Inc's revenue for the next 4 years is 186%.

N/A
Past Growth
186%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
VistaGen Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

Net Income Estimate
VistaGen Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-86%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VTGN's stock price target?
Price Target
13.26 USD

According to Wall Street analysts, the average 1-year price target for VTGN is 13.26 USD with a low forecast of 12.12 USD and a high forecast of 15.75 USD.

What is VistaGen Therapeutics Inc's Revenue forecast?
Projected CAGR
186%

The compound annual growth rate of VistaGen Therapeutics Inc's revenue for the next 4 years is 186%.

Back to Top